BRIEF published on 04/23/2025 at 09:10, 11 months 16 days ago BioNxt Solutions Advances in MS Treatment Study Multiple Sclerosis Cladribine Drug Delivery Innovation BioNxt Solutions Bioequivalence Study
PRESS RELEASE published on 04/23/2025 at 09:05, 11 months 16 days ago BioNxt Solutions Prepares for Human Bioequivalence Study For MS BioNxt Solutions Inc. reports advanced preparation for human bioequivalence study of BNT23001, a novel sublingual thin-film Cladribine formulation for Multiple Sclerosis treatment BioNxt Solutions Inc. Multiple Sclerosis Treatment Sublingual Thin-Film BNT23001 Human Bioequivalence Study
BRIEF published on 03/15/2025 at 00:05, 1 year ago BioNxt Solutions Closes Final Tranche of Convertible Debenture Offering Private Placement Convertible Debenture Warrants Financing BioNxt Solutions
PRESS RELEASE published on 03/15/2025 at 00:00, 1 year ago BioNxt Solutions Announces Closing of Final Tranche of Fully Subscribed Convertible Debenture Unit Private Placement BioNxt Solutions Inc. completes final tranche of convertible debenture Offering for $900,000. Funds to be used for product dev, IP, debt repayment, and working capital Private Placement Convertible Debenture Healthcare BioNxt Solutions Inc. Drug Delivery Technologies
BRIEF published on 03/01/2025 at 01:40, 1 year 1 month ago BioNxt Solutions Secures $1.6 Million in Convertible Debenture Private Placement Private Placement Convertible Debenture Investment BioNxt Solutions Proceeds Utilization
PRESS RELEASE published on 03/01/2025 at 01:35, 1 year 1 month ago BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement BioNxt Solutions Inc. closes first tranche of convertible debenture units Offering, raising $1.6M. Proceeds for product development, IP filings, debt repayment, and working capital Private Placement BioNxt Solutions Inc. Intellectual Property Product Development Convertible Debenture Units
BRIEF published on 02/24/2025 at 15:05, 1 year 1 month ago BioNxt Solutions Launches Debenture Unit Financing Private Placement Regulatory Approvals Convertible Securities Debenture Units Compensation Warrants
PRESS RELEASE published on 02/24/2025 at 15:00, 1 year 1 month ago BioNxt Solutions Announces Debenture Unit Financing BioNxt Solutions Inc. announces a non-brokered private placement of debenture units and Finders Warrants, expecting gross proceeds of up to $2,500,000, subject to regulatory approvals Private Placement BioNxt Solutions Inc. Regulatory Approvals Debenture Units Finders Warrants
BRIEF published on 02/22/2025 at 01:40, 1 year 1 month ago BioNxt Solutions Inc. Clarifies Promotional Activity Agreements Investor Relations German Market BioNxt Solutions Promotional Activities Option Plan
PRESS RELEASE published on 02/22/2025 at 01:35, 1 year 1 month ago Clarification of Promotional Activities BioNxt Solutions Inc. provides a clarification on engaging Apaton Finance GmbH and Cayo Ventures GmbH for investor relations services in Germany and Switzerland Investor Relations Services BioNxt Solutions Inc. Apaton Finance GmbH Cayo Ventures GmbH German Translations
Published on 04/10/2026 at 02:15, 6 hours 15 minutes ago Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Published on 04/10/2026 at 01:05, 7 hours 25 minutes ago Pathfinder Ventures Inc. Announces Tranche Closing of Financing and Extension of Private Placement
Published on 04/10/2026 at 00:00, 8 hours 30 minutes ago Redwood AI Announces Upgraded Cloud-Based Reactosphere Platform with Enhanced Security and Expanded Core Capabilities
Published on 04/09/2026 at 23:15, 9 hours 15 minutes ago Digi Power X Enters into Amended and Restated Sales Agreement
Published on 04/10/2026 at 08:00, 30 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/10/2026 at 07:00, 1 hour 29 minutes ago Lindt & Sprüngli completes buyback of own shares and participation certificates ahead of schedule and launches new buyback program in May
Published on 04/09/2026 at 22:00, 10 hours 29 minutes ago Invitation - First Quarter 2026 Trading Update Conference Call
Published on 04/09/2026 at 18:35, 13 hours 55 minutes ago Availability of proxy documents for the Combined General Meeting of April 30, 2026
Published on 04/09/2026 at 15:57, 16 hours 32 minutes ago Filing of CNP Assurances SA 2025 universal registration document and 2025 Solvency and Financial Condition Reports
Published on 04/09/2026 at 07:00, 1 day 1 hour ago bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
Published on 04/08/2026 at 18:02, 1 day 14 hours ago Publication of the 2025 Universal Registration Document
